2-bromo-N-pyrimidin-4-yl-acetamide | 787628-90-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-bromo-N-pyrimidin-4-yl-acetamide
• 英文别名: 2-bromo-N-pyrimidin-4-ylacetamide
• CAS: 787628-90-4
• 化学式: C₆H₆BrN₃O
• 分子量: 216.037
• InChiKey: HFHNLWNFYUFJJS-UHFFFAOYSA-N

物化性质

• 沸点：
  411.8±25.0 °C(Predicted)
• 密度：
  1.768±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-N-pyrimidin-4-yl-acetamide 、 (R)-奎宁环-3-基 羟基二(2-噻吩基)乙酸酯 在 三乙胺 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 3.0h， 生成 (R)-3-(2-hydroxy-2,2-di-thiophen-2-ylacetoxy)-1-(pyrimidin-4-ylcarbamoylmethyl)-1-azoniabicyclo[2.2.2]octane bromide
  参考文献：
  名称：

  [EN] QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  [FR] COMPOSES ORGANIQUES

  摘要：

  公开号：

  WO2004096800A3
• 作为产物：
  描述：

  4-氨基嘧啶 、 溴乙酰溴 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.5h， 生成 2-bromo-N-pyrimidin-4-yl-acetamide
  参考文献：
  名称：

  [EN] QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  [FR] COMPOSES ORGANIQUES

  摘要：

  公开号：

  WO2004096800A3

文献信息

• Organic Compounds
  申请人：Press Neil John

  公开号：US20090048281A1

  公开（公告）日：2009-02-19

  Compounds of Formula (I); in salt or zwitterionic form wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式（I）的化合物；以盐或双电离形式存在，其中R1，R2，R3和R4具有规范中指示的含义，可用于治疗由肌肉型M3受体介导的疾病，尤其是炎症性或阻塞性呼吸道疾病。还描述了含有该化合物的制药组合物和制备该化合物的过程。
• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic M3 receptors
  申请人：Novartis AG

  公开号：US08168654B2

  公开（公告）日：2012-05-01

  Compounds of formula I in salt or zwitterionic form wherein, wherein R1, R2, R3, and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  化合物I的盐或双离子形式，其中R1、R2、R3和R4的含义如规范所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有该化合物的制药组合物和制备该化合物的过程。
• Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
  申请人：Novartis AG

  公开号：US08084463B2

  公开（公告）日：2011-12-27

  Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式（I）的化合物；以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的疾病，尤其是炎症性或阻塞性呼吸道疾病。还描述了包含这些化合物的制药组合物和制备这些化合物的过程。